PlainRecalls
ModerateClass IITerminated

FDA Drug recall · Reported April 28, 2021

Minivelle (estradiol transdermal system) Delivers 0.075 mg/day, 8 patches/box, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. by: Noven Therapeutics, LLC Miami, Florida 33186, NDC 68968-6675-8

Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patien…

Recall #
D-0336-2021
Affected scope
12060 cartons
Initiated
April 16, 2021
Verify with FDA Drug →
View my saved recalls

Noven Pharmaceuticals Inc recalled Minivelle (estradiol transdermal system) Delivers 0.075 mg/day, 8 patches/box, Rx only, M… - a moderate-severity action.

Minivelle (estradiol transdermal system) Delivers 0.075 mg/day, 8 patches/box, Rx only, M… was recalled by Noven Pharmaceuticals Inc in April 28, 2021. Reason: Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to t…. Check the official notice for the remedy. Verify recall #D-0336-2021 with the FDA Drug before acting.

The recall

Noven Pharmaceuticals Inc issued this moderate-severity FDA Drug recall-Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to t….

Moderate
severity level
Class II
classification
April 28, 2021
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0336-2021 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 3 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Cosmetics & Personal Care recalls over time

Where this recall sits in its category - 1,371 cosmetics & personal care recalls on record

0100200300400 20052008201120142017202020232026 33
Severity1906864652High severity (most serious)Moderate severityLow severity
Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Minivelle (estradiol transdermal system) Delivers 0.075 mg/day, 8 patches/box, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. by: Noven Therapeutics, LLC Miami, Florida 33186, NDC 68968-6675-8

Reason for recall

Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Moderate (Class II)
Status Terminated
Recall number D-0336-2021
Date reported April 28, 2021
Date initiated April 16, 2021
Recalling firm Noven Pharmaceuticals Inc
Firm location Miami, FL
Affected scope 12060 cartons
Distribution Nationwide within the United States

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-0336-2021) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting, recall details can be updated.
  • Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
Minivelle (estradiol transdermal system) Delivers 0.075 mg/day, 8 patches/box, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. by: Noven Therapeutics, LLC Miami, Florida 33186, NDC 68968-6675-8. Recalled by Noven Pharmaceuticals Inc. Units affected: 12060 cartons.
Why was this product recalled?
Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin.
Which agency issued this recall?
This recall was issued by the FDA Drug on April 28, 2021. Severity: Moderate. Recall number: D-0336-2021.
Where was the recalled product distributed?
Distribution: Nationwide within the United States.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Compare this recall with Ice Pop, D'Dioses Cookies Cream, 1 Bar (81.7 g), with UPC 7… → · All Cosmetics & Personal Care recalls

This recall: FDA Drug, reported April 28, 2021. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026